Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Innovative Implantable Occluder Treats Isolated ASDs

By HospiMedica International staff writers
Posted on 27 Jul 2021
A new atrial septal defect (ASD) occluder aims to establish a new standard of care for structural heart treatments. More...


The atHeart Medical (Baar, Switzerland) reSept ASD Occluder is a low-profile, metal-free, bioresorbable implant designed to reduce the risk of complications associated with long-term presence of metal in the heart. The occluder is made of bioresorbable filaments connecting two polyester fabric patches, which contain radiopaque markers. Delivered through a 12F sheath and over a standard guidewire, the device is fully deployed with the guidewire in place, providing the opportunity to reattach and reposition when necessary.

After endothelialization, the filaments slowly resorb, with complete resorption demonstrated in-vitro at 24 months. In addition, reSept has been designed to preserve future treatment options requiring surgery; the polyester fabric and the radiopaque markers remain, which may be useful for future transseptal procedure planning. Available in three sizes, the reSept ASD Occluder supports closure of defects of 4-22mm. The device is currently undergoing a prospective global multi-site clinical investigational device exemption (IDE) trial that will enroll up to 250 patients.

“The metal-free frame of the reSept ASD Occluder provides a low-profile that over time is replaced by the patient's tissue, leaving minimal implant behind and restoring a more natural septum when compared to current occluder devices,” said interventional cardiologist Saibal Kar, MD, of Los Robles Regional Medical Center (Thousand Oaks, CA, USA), co-principal investigator of the IDE trial. “This provides a unique opportunity for physicians to effectively address ASDs while being mindful of our patient's potential need for subsequent transseptal procedures.”

An ASD is a congenital defect resulting from an abnormal formation of the septum that divides the upper chamber into a left and right atrium. This can result in blood flow between the two upper heart chambers through the ASD, forming a shunt. As a result, pressure in the lungs may build up, causing less oxygen in the blood. Symptoms can include difficulty breathing, frequent respiratory infections in children, palpitation, and shortness of breath with activity.

Related Links:
atHeart Medical


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.